Lincoln International’s Global Healthcare Group Announces Strong Results in 2022

Lincoln International’s global Healthcare Group enjoyed another consecutive year of record-setting mergers and acquisitions (M&A) deal volume, average deal size and a record backlog heading in to 2023. Our performance is especially notable given global healthcare M&A volumes saw a modest pull back in 2022 brought on by instability in the labor market, higher inflation and interest rates, pressure on reimbursements and the waning influence of COVID-19-era government-funded supports.

Despite these macro influences, we expect 2023 to be another active year for healthcare dealmaking as industry players and private equity utilize M&A as a strategy to keep pace with the ever-increasing complexities across healthcare access, quality and cost; regulatory pressures; reimbursement rates; software and technology integration; payment reforms and advances in pharma and medical technology.

Our team has deep domain expertise and transaction experience across a number of high growth areas of the global healthcare economy including:

  • Animal health
  • Behavioral and mental health
  • Fertility and women’s health
  • Healthcare IT and tech-enabled services
  • Home and community based care
  • Labs and lab services
  • Payor services and employer-funded insurance services
  • Pharma and medtech outsourcing
  • Physical / occupational / speech therapy and rehab
  • Physician services and ambulatory care
  • Value-based care enablement
  • Revenue cycle management

Summary

  • Lincoln International's Global Healthcare Group announces strong results in 2022.

Select Notable 2022 Healthcare Transactions

Related Perspectives

Meet Our Senior Team in Healthcare